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The human proximal colon has been considered a favourable site to deliver drugs for local and systemic
treatments. However, modified dosage forms face a complex and dynamically changing colonic environ-
ment. Therefore, it has been realized that in addition to the use of biorelevant media, the hydrodynamics
also need to be reproduced to create a powerful in vitro dissolution model to enable in vivo performance
of the dosage forms to be predicted.
A novel biorelevant Dynamic Colon Model (DCM) has been developed which provides a realistic envi-
ronment in terms of the architecture of the smooth muscle, the physical pressures and the motility pat-
terns occurring in the proximal human colon. Measurements of pressure inside the DCM tube confirmed
a direct association between the magnitude of the pressure signal with the occlusion rate of the mem-
brane and the viscosity of the fluid.
The dissolution profile and the distribution of the highly soluble drug, theophylline, were assessed by
collecting samples at different locations along the DCM tube. Differences in the release rates of the drug
were observed which were affected by the sampling point location, the viscosity of the fluid and the mix-
ing within the DCM tube. Images of the overall convective motion of the fluid inside the DCM tube
obtained using Positron Emission Tomography enabled relation of the distribution of the tracer to likely
areas of high and low concentrations of the theophylline drug.
This information provides improved understanding of how extensive phenomena such as supersatura-
tion and precipitation of the drug may be during the passage of the dosage form through the proximal
colon.
 2016 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The environment of the human colon is considered favourable
for systemic and local delivery of drugs [1,2]. The neutral pH, the
reduced digestive enzymatic activity, the higher responsiveness
to absorption enhancers (e.g. chitosan) [3] and the much longer
transit times compared to the upper gastrointestinal (GI) tract
[4], make the colon an attractive site for drug delivery.
Predictive dissolution methods can contribute to a reduction in
or refinement of in vivo studies during the design, development
and evaluation of drug delivery systems. Thus, the establishmentof an in vivo-in vitro correlation is of great importance. Tempera-
ture, pH, ionic strength, buffer capacity, presence of surfactants
and/or digestive enzymes, greatly influence the release of the drug
from modified-release dosage forms [5]. However, it has been rea-
lized that both physicochemical characteristics of the gastroin-
testinal fluids as well as hydrodynamics need to be reproduced
in order to make a powerful in vitromodel to predict in vivo perfor-
mance [5–7]. Existing compendial dissolution methods oversim-
plify the complex and dynamic environment of the human colon
[8]. Thus, apart from the application of the biorelevant media in
the dissolution methods [9–13], attempts have been made to
improve the bio-relevance of the hydrodynamic and mechanical
conditions in dissolution methods [5,14–17].
A physiologically realistic engineering intestinal model needs to
be able to reproduce the widely accepted law of the intestine [18],
which states that the colonic fluids move in the digestive tract due
to the combined ascending excitatory (muscle contraction)
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ation) [19]. Furthermore, the structure and the activity of the
smooth muscle act to regulate the mixing, transport and the resi-
dence times of the colonic fluids [20,21]. In particular, the presence
of taeniae (the thick layer of the longitudinal muscle) and semilu-
nar folds, which form the characteristic pockets in the colon which
are termed the haustra, seems to play a major role in the regulation
of colonic fluid transit through the colon [21].
Advances in manometry [22] and in non-invasive monitoring
systems [23,24] have provided insights on colon motility and tran-
sit times; demonstrating the complex and dynamic environment
that a modified dosage form is exposed to during its passage
through the lower GI tract. Five types of propagating motor pat-
terns have been identified by use of high – resolution fibre – optic
manometry [22]. Four of them (cyclic motor, short single, long sin-
gle and occasional retrograde motor pattern) are related to low –
amplitude propagating sequences (range of average values: 2–
10 mmHg) and form the majority of the motility events [22]. The
remaining pattern forms high – amplitude propagating sequences
(PSs) (>116 mmHg) [22]. The low – amplitude PSs were as likely to
be associated with colonic movements as high - amplitude PSs
[25]. However, the low – amplitude PSs seem to be related mainly
to the mixing of fluids (segmentation) [26] whereas high – ampli-
tude PSs cause mass movements (peristalsis) of the colonic fluids
[27]. However, the pressure signal of the catheter is affected by
the viscosity of the colonic fluids [28]. Arkwright et al. [28] showed
that the predetermined amplitude of the applied pressure on a
flexible wall was not the same as the pressure measured by the
catheter placed inside the elastic tube filled with viscous lumen.
Thus, in vitro models should take this into consideration. Other-
wise, it is likely that the applied pressures in the lumen by the flex-
ible tube, like in case of the large intestine simulator TIM-2 [29],
will not accurately reflect the physical amplitudes.
In vivo studies of the human colon have shown that other fac-
tors, in addition to the PSs, affect the propulsion and the mixing
of the colonic fluids [25]. The travel distance of the PSs, the viscos-
ity [30] and the reflux of 50% of the bolus, slow the propulsion of
the fluids [25]. Thus, the mixing of the colonic fluids is served with
the combination of these parameters causing ‘to and fro’ motion of
the contents.
Most of drugs have been targeted at the proximal human colon
(i.e. caecum and ascending section) because it is a good potential
site for absorption with its high water content, larger surface area
as well as higher bacterial activity [31]. The volume of the colonic
fluids does not differ significantly in fasted and fed state [32] and
varies with a range 10–125 mL [33]. However, magnetic resonance
imaging studies have shown the fluids are distributed along the
colon in the form of pockets [32]; for instance, 13 mL could be dis-
tributed among four pockets (i.e. haustra) [33].
It is clear that apart from the use of biorelevant media, the
proper simulation of the hydrodynamics in proximal colon should
be performed via the reproduction of the architecture of the colon.
Moreover, the volume and the spread of the fluids will also affect
the dissolution and the distribution of the drug along the proximal
colon. The distribution of the drug could be also considered as a
parameter which might determine the fraction of the absorptive
surface area of the colon wall on which the drug will be exposed.
Thus, it is also critical to understand how colon motility influences
not only the dissolution profile but also the distribution of the drug
within the proximal colon.
The aim of this study was to develop a computer – controlled
Dynamic Colon Model (DCM), in order to understand the colonic
behaviour of an extended release oral dosage form exposed to a
more realistic colonic environment. Specifically the model was
designed to reproduce the anatomy and propagating motor pat-
terns within the human proximal colon. A solid phase catheterwas used to monitor the pressure forces generated by the wall
motion within the DCM and Positron Emission Tomography (PET)
was used to visualize the overall convection of fluids. The dissolu-
tion behaviour of an extended release dosage form (theophylline)
was assessed in different viscous media within the DCM; the dif-
ferent media represented the dewatering process which takes
place in the human colon.2. Materials and methods
2.1. Materials
Sodium carboxymethylcellulose (NaCMC) of 90,000 and
700,000 molecular weight was purchased from Sigma (St., Louis,
USA). Theophylline anhydrous and potato starch were bought from
Acros Organics (Loughborough, UK). Sodium hydroxide, hydrochlo-
ric acid (1 M), potassium hydrogen (KH2PO4) and dihydrogen phos-
phate (K2HPO4) were purchased from Sigma (St., Louis, USA). The
radioactive solution of radionuclide 18F, used in PET experiments,
was provided from the School of Physics and Astronomy of the
University of Birmingham, UK.
2.2. Manometric measurements
A solid state catheter manufactured by Unisensor (Unisensor
AG, Attikon, CH-8544, Switzerland) was used for the experimental
studies. The catheter was 2.6 mm in diameter and contained 1
pressure sensing element. The calibration of the pressure sensor
was performed by placing the catheter in a tube filled with distilled
water. The system was well sealed with no air or water leakage.
Then, using a hand pump manometer, predetermined pressure
intervals were applied within the range of 0–300 mmHg and the
voltage output of the catheter was recorded. In order to measure
local pressure events generated by the oscillation of a single unit
of the DCM tube a modified version of the apparatus used by Ark-
wright et al. [28] was developed (supplementary material). Since
the interpretation of the manometric data is affected by the viscos-
ity of the fluids [28], the signal output of the catheter was recorded
in different solutions of NaCMC (0.25, 0.50 and 0.75%, (w/w)) for
fixed membrane occlusion degree (73%; avoiding physical contact
with the catheter) and occlusion rates of 4.3 mm s1, 8.5 mm s1
and 16.6 mm s1.
2.3. Dynamic Colon Model (DCM)
A schematic representation of the novel DCM tube is presented
in Fig. 1. The tube consists of ten segments with 20 cm total length
and diameter 5 cm, to match the average values that typically seen
in the human proximal colon [34]. Inflation and deflation of the
membrane of each segment is controlled by a hydraulic system
producing an antegrade (forward) wave at a speed of 2 cm s1
which is representative of the human colon [22,25].
Fig. 2a shows the membrane’s displacement profile of each indi-
vidual segment and the overall profile of the propagating wall
motion (Fig. 2b). In order to reproduce the intestine law (i.e. con-
traction of the first segment with the simultaneous relaxation of
the proximal segment), the profile of the wave of the DCM wall
was set up as follows: (1) the membrane of the first segment
was inflated whereas in the second it was deflated at the same
speed 1.6 cm s1; (2) When the first segment reaches the maxi-
mum occlusion degree (i.e. 73%), it stays at this position for 1 s
before going back to its neutral position with a speed of
0.35 cm s1. The slower speed was used in order to mimic the
relaxation of the colon wall. In addition, keeping the segment at
the contraction stage for 1 s prevents backflow as shown in
a 
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Fig. 1. 3D model of DCM tube using ANSYS Spaceclaim 2015. The DCM tube is consisted by: (a) a hemispherical acrylic body which represents the caecum; (b) the flexible
membrane; (c) the inlet which represents the ileocolonic junction zone; (d) the triangular configured segment with the characteristic haustrum; (e) a rigid siphon which
represents the hepatic flexure; S1, S2 and S3 represent the location of the sampling points along the DCM tube.
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Fig. 2. (a) Profile of contraction-break-relaxation cycle of each segment; (b) profile of the travelling peristaltic wave along the artificial colon tube; (c) a forwardly fluid flow is
formed by introducing a standing period (break) at the contraction stage of the starting segment.
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that the motion within the DCM was representative of that within
the human colon and minimized backflow within the DCM.
2.4. Dissolution experiments
The dissolution profile of the theophylline released from the
NaCMC (90,000) based tablet was assessed in different viscous
media and under a fixed motion of DCM flexible wall which was
engineered to mimic the main motility pattern observed in human
proximal colon. The tablet was directly introduced into the pre-
filled DCM tube, assuming that the dosage form reached the
human colon intact. This approach is not far from the reality since
studies have shown that colon-specific coated formulations reach
the lower GI tract intact [35].NaCMC(90,000) based tablets of 500 mg were prepared for the
dissolution experiments. The composition was as follows: 50%
(w/w) theophylline, 44% (w/w) NaCMC(90,000), 5% (w/w) potato
starch and 1% (w/w) silicone dioxide. The excipients were sieved,
mixed manually for 10 min and tableted using a single die tablet-
ing machine (Kilian, Coln, D) with a piezoelectric load washer (Kis-
tler, Winterthur, CH) fitted with flat-faced 9.8 mm punch. A load
pressure of 1961.2 bar was applied. The cylindrical tablets had a
final weight of 500 ± 15 mg.
The dissolution experiments were set up based on two assump-
tions: (i) the DCM tube was placed horizontally in accordance with
the normal reclining position of patients during manometric,
scintigraphy and MRI procedures; (ii) it is assumed that the DCM
operates in the fed state in which more propagating sequences of
pressure waves are taking place in proximal colon [22]. The DCM
12 K. Stamatopoulos et al. / European Journal of Pharmaceutics and Biopharmaceutics 108 (2016) 9–17tube was filled to 50% full which corresponds to 100 mL of
NaCMC(700,000) using solutions with different concentrations (0.25
and 0.50%, w/w). This volume was chosen in order to compare
the results with the published data obtained from the mini volume
USP 2 [36]. In addition, 100 mL is close to the overall volume that a
dosage form is likely to be exposed to during its passage through
the human colon [37].
The frequency of the pressure events during the dissolution test
was set up to represent values within the human colon previously
reported in the literature [25]. Thus, the total duration time of the
dissolution experiments was selected to be 560 min and every
5 min an antegrade propagating sequence (APS) was applied. Sam-
ples were collected from three different locations: at the beginning
(S1), in the middle (S2) and at the end (S3) of the DCM tube in
order to evaluate the distribution of the released drug. The samples
were collected at predetermined time intervals (5, 10, 30, 60, 120,
240, 360, 480 and 560 min). Subsequently, all the samples were
passed through a 0.4 lm PTFE filter [36] prior to the quantitative
analysis of theophylline which was performed according to Stam-
atopoulos et al. [36]. The temperature during the dissolution
experiments was maintained at 37 C using a 300 W infrared cera-
mic lamp. The volume of the medium removed at each time point
was replaced with fresh media.
2.5. Positron Emission Tomography (PET) experiments
The Positron Emission Tomography system at the University of
Birmingham was used in order to assess the mixing process within
the DCM tube under APS waves. Details of the PET system can be
found in Broadbent et al. [38]. Fig. 3 illustrates the DCM setup
between the two PET cameras and the coordinate system used as
a reference. The half-filled DCM tube was placed between the
two positron cameras and 1 mL of radiolabelled water was injected
in the first segment through a hole of 1 cm£, which represents the
human ileocolonic junction. Ten antegrade waves, with 10 s time
delay between them, were applied. As in scintigraphy studies, each
PET image shows the distribution of the radioactive solution along
the length of the DCM tube. The PET data were used to correlate to
the dissolution data of the theophylline tablets.3. Results and discussion
3.1. Determination of the pressures inside a DCM segment using
manometry
Manometry is a well-established method for recording the
motility events in the lower GI tract as well as diagnosing abnor-
malities in the human colon [39]. However, manometry measure-
ments are affected by the viscosity of the fluids [28]. Thus, thexy
z
A
B
PET camera
a
Fig. 3. (a) DCM tube (A) in between PET cameras coupled with the hydraulicpressure signal generated from the oscillation of the flexible wall
of DCM tube is recorded using fluid of increasing viscosity. Fig. 4
shows the measured pressures obtained with using fluids of differ-
ent NaCMC(700,000) concentrations. It is clear that as the viscosity is
increased the measured pressure signal is also increased. In addi-
tion, the solid state catheter used in this study can record non-
occluding events (i.e. no physical contact of the membrane with
the catheter). This is important when other motility patterns rather
than high-amplitude propagating sequences need to be repro-
duced in in vitro models in order to assess the performance of
the dosage forms, since the majority of the motility events are of
low amplitude [40]. It is noticed that the higher the rate of occlu-
sion, the sharper is the peak of recorded pressure. These observa-
tions were in agreement with that described by Arkwright et al.
[28]. The measured pressure in water was 1 mmHg regardless of
the membrane occlusion rate whereas significant increase in pres-
sure signal was observed from 2.5 to 5 mmHg when the concentra-
tion of NaCMC wasP0.62% (w/w) and the occlusion rate increased
from 4.3 mm s1 to 16.6 mm s1. The measured pressures gener-
ated by the wall motion of the DCM tube were within the range
of in vivo amplitudes recorded with the use of high resolution
catheters [22]. Dinning et al. [22], showed that the amplitudes
recorded in proximal colon prior to a meal were below 2 mmHg
whereas after meal were between 2 and 4 mmHg. However, it is
not possible for the authors to know the viscosity of the colonic flu-
ids or the occlusion degree of the colon wall, during the recording
time, in order to assess the impact of these two parameters on the
interpretation of the manometric measurements. Nevertheless, the
viscosity of the colonic fluids is likely to increase during the exper-
imental study (4 h manometric recording time) since the net
absorption rate of the water observed in human colon is
2.7 ± 0.3 mL min1 [41]. In addition, high pressure signals of
100 mmHg magnitude were only observed when the membrane
touched and partially squeezed the pressure sensor of the solid
state catheter used in our study. Thus, apart from the high ampli-
tude propagating sequences, the in vivo values recorded in proxi-
mal colon [22] might represent mainly non-occluding events
under continuously variable viscosity of the colonic fluids. There-
fore, the experimental conditions in our study and hence the mea-
sured pressures could be considered biorelevant when compared
with the available in vivo data.3.2. Release profile of theophylline in different viscous media
Fig. 5 shows the dissolution profile of the theophylline in vis-
cous media which was obtained from the three different sampling
points, located at the beginning, at the middle and at the end of the
DCM tube. The results for the 0.25% NaCMC(700,000) (w/w) solution
(Fig. 5a), show that there was an unequal distribution of thePET camera 1
PET camera 2 
Hydraulic 
unit
PC
x 
y 
b
system (B); (b) schematic representation of the DCM – PET configuration.
Fig. 4. Measure changes in pressure on the lumen for different NaCMC(700,000)
concentrations ( 1.00%,  0.75%, . 0.62%, r 0.50%, j 0.25%, + 0.00%, (w/w)) and
membrane occlusion rates: (1) 4.3 mm s1; (2) 8.5 mm s1; (3) 16.6 mm s1.
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release rate. The highest release rate, and hence the highest con-
centration, was observed at the beginning of the DCM tube, where
the tablet was initially located, followed by the second sampling
point and finally by the third one located at the end of the tube,
as expected. The dissolution profile of the theophylline in 0.50%
NaCMC (w/w) (Fig. 5b) followed the same order as in 0.25% NaCMC
(w/w) in terms of the release rate according to the sampling point.
The results showed relatively similar release rate of the drug in S1
for the 0.50% NaCMC (w/w) to that one in 0.25% NaCMC (w/w) for
the same sampling point, but very slow for the other two sampling
points (i.e. S2, S3). In particular, at the following sampling time
points, i.e. 2, 6 and 8 h, the released drug (%) in 0.25% NaCMC
(w/w) was within the range of 3.7%–30.7%, 15%–76.6% and
34.8%–85.5% respectively, whereas in 0.5% NaCMC was 0.2%–
29.5%, 0.5%–82.4% and 3%–76.7%. The lower values in all above
ranges correspond to S3 and the high ones to S1. These results
demonstrated several key features. Firstly, the fluctuations in the
drug concentrations and hence of the dissolution profile, most
likely reflect the ineffective transport of the drug along the tube,
resulting in the formation of areas with high accumulation of the
drug; especially at the beginning of the DCM tube, at which the
tablet had been introduced. Furthermore, the distribution of the
drug in 0.50% NaCMC (w/w) solution was less efficient compareda 
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Fig. 5. Dissolution curves of theophylline obtained from three different sampling points
were performed in (a) 0.25% and (b) 0.50% NaCMC(700,000) (w/w) solutions adjusted at pH
dissolution profile theophylline (n = 6).to 0.25% NaCMC (w/w), as anticipated. In the case of 0.50% NaCMC
(w/w), most of the drug was accumulated mainly at the beginning
of the tube giving release rates close to those obtained in 0.25%
NaCMC (w/w). However, this does not mean a faster hydration of
the tablet and hence a faster release of the drug in more viscous
media [36]. It means that beside the slower release rate of the drug,
the inadequate transport in 0.50 NaCMC (w/w) solution leads to
high accumulation of the drug molecules in a small area, which
may be of value in the local treatment of the ascending colon. In
contrast, the distribution of the drug in 0.25% NaCMC (w/w) seems
to be more effective.
Second, higher variability was observed in the dissolution data
obtained with using 0.50% NaCMC (w/w). It was noticed, by plot-
ting separately the dissolution data of two single different runs,
that the dissolution curves of S1 and S2, to a much lesser extent
of S3, showed completely different profile (Fig. 6) compared to
the dissolution curves of S1 and S2 obtained in the less viscous
solution (0.25% NaCMC (w/w)). It seems that except the non-
homogeneous distribution of the drug along the DCM tube, the
location as well as the erosion of the tablet due to wall motion
might affect the release rate of the drug. Indeed, images from the
interior of the DCM tube (Fig. 7A) showed fragments of the dosage
form which were found to be located either in the cavity of the
membrane (Fig. 7B) or on the connection point, the so-called
semilunar folds, between the two segments. It seems that if the
tablet is located within the cavity of the membrane then the disin-
tegration could be intensive, since the membrane will squeeze and
break the dosage form. These observations in combination with the
poor distribution of the released drug could explain the differences
observed in dissolution profiles and consequently the irregular
absorption profiles observed from extended release tablets [5].
Moreover, observations of the final solution of 0.25% NaCMC (w/
w) (supplementary material) collected after the end of the dissolu-
tion experiments, showed that the dosage form had been disinte-
grated in small agglomerates.3.3. Visual identification of propagating wall motion of DCM tube
using Positron Emission Tomography (PET)
In order to better understand the fluctuations in the concentra-
tion of the drug along the tube caused by the wall motion of DCM,
PET experiments were performed. This was possible by recording
the intensity of the radioactive tracer injected at the beginning of
the tube, during repeating APSs waves with 10 s time delay. This
time delay was allowed to represent sequential waves whilst con-
densing the overall time of the experiment to manage the lifespanb
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along the length of the DCM tube (r S1; j S2; N S3). The dissolution experiments
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Fig. 6. Dissolution profile of theophylline of two different runs in 0.50% NaCMC (w/w) adjusted at pH 7.4 using phosphate buffer. The dissolution curves were obtained from
three different sampling points along the length of the DCM tube (r S1; N S2; j S3). Temperature was 37 C; Error bars for the dissolution profile of theophylline (n = 3).
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Fig. 7. (A) Images of the cross section of the DCM tube and (B) schematic illustration of the in vitromodel along the x axis, showing the position of the partially disintegrated
tablet in two separated runs of the dissolution experiments.
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the fluid to become static between waves.
PET images of the 0.25% NaCMC solution (Fig. 8) showed a grad-
ual distribution of the radioactive tracer along the DCM, with only
a small amount of tracer detected at the very end of the tube even
after 10 waves (Fig. 8d). Higher intensities were observed in the
areas at which S1 and S2 are located. In addition, although, the tra-
cer intensity around points S1 and S2 seems to be approximately of
the same magnitude after 10 waves (with a slight lower intensity
at S1), the corresponding dissolution curves showed greater differ-
ences. Nevertheless, it has to be acknowledged that the PET is an
accelerated mimic of the dissolution test, since an APS wave was
occurring every 10 s compared with an APS wave every 5 min in
the dissolution experiments. In addition, the drug is gradually
released from the tablet resulting in a continuous ‘‘injection” in
the solution making actually the dissolution experiment a repeat-
ing cycle of the PET experiment. Practically this means that a high
concentration of the drug will always be observed at the beginning
of the DCM tube, representing the injection point in PET experi-
ments (Fig. 8a), and after several APSs the drug will be gradually
distributed along the tube as shown in Fig. 8b–d.The PET images represent an approximation of the distribution
of the drug giving information about the zones of high and low
concentrations. In particular, only a small portion of the tracer
reached the very end of the tube, where the S3 is located
(Fig. 8d). This explains why low release rates (e.g. 45% @ 9 h) were
obtained in the dissolution profiles at point S3 in 0.25% NaCMC (w/
w). In addition, radioactive tracer was mainly accumulated around
point S2 whereas a slight decrease was observed at S1 (Fig. 8d). The
same pattern was observed in dissolution test in which the release
rate was increasing and was getting closer to that of S1 as the end
of the experiment was reached.
Further increase in viscosity leads to a different profile of the
distribution of the radioactive tracer. With 0.50% NaCMC (w/w)
(Fig. 9) a significant amount of the tracer remained at the begin-
ning of the tube whereas another considerable amount appeared
between the points S2 and S3 after 5 (Fig. 9c) and 10 (Fig. 9d) APSs
waves. However, close to S2 a slight increase in the intensity of the
radiolabelled solution was observed due to the backward tailing of
the radioactive tracer caused by the backflow formed as the APSs
wave reached the very end of the tube. In addition, no tracer
reached the very end of the tube explaining why very low release
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Fig. 8. PET images of (a) injection, (b) first wave, (c) fifth wave and (d) tenth wave
using 0.25% NaCMC (w/w).
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Fig. 9. PET images of (a) injection, (b) first wave, (c) fifth wave and (d) tenth wave
using 0.50% NaCMC (w/w).
Table 1
Comparison of the release rates of the theophylline obtained from Dynamic Colon
Model (DCM) with the published data obtained from mini volume USP 2.
Time (h) %NaCMC (w/w)
0.25% 0.50%
DCMa Mini USP 2b DCMa Mini USP 2b
2 3.7–30.7 10.0–15.0 0.2–29.5 10.0–12.0
6 15.0–76.6 30.0–40.0 0.5–82.4 30.0–50.0
8 34.8–85.5 45.0–58.0 3.0–76.7 40.0–55.0
a The low limit of the ranges corresponds to the third sampling point (S3) and the
high one to the first sampling point (S1).
b The low values correspond to the SP1 (close to the surface of the medium) and
the high to the SP2 (close to the tip) [36].
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based on the dissolution data obtained from samples collected in
S3 location.
Furthermore, due to the DCM wall motion and the partial disin-
tegration of the tablet, fragments of the dosage form were foundseveral centimetres from the first segment of the model (Fig. 7A).
Assuming that the drug will be mainly accumulated around the
fragments, areas of high drug concentrations (Fig. 7B) might be dif-
ferently distributed along the DCM tube with respect to the spots
of high intensities of the tracer, as indicated in PET images of
0.50% NaCMC (w/w) (Fig. 9). In particular, PET experiments showed
one spot close to the injection point and another one several cen-
timetres further from the S2 (Fig. 9d). However, elongation of the
first spot was observed towards the direction of the wave whereas
lengthening of the second spot was appeared mainly in the oppo-
site direction due to the backflow which is stronger as getting clo-
ser to the very end of the tube. Thus, tracers of the radioactive
solution were detected close to S2. Thus, this ‘to and fro’ fluid
motion will also affect the distribution of the drug. Hence, if the
tablet or fragments are located between S1 and S2, it is likely that
‘‘elongation” of the high drug accumulation area might be occurred
in both directions (Fig. 7B; first case). As a further consequence the
release rates of the drug obtained from S1 to S2 will be approxi-
mately similar (Fig. 6b). In contrast, when the tablet remains in
the first segment and only a small fragment is located a few cen-
timetres further, the distribution of the drug might be looked like
as in the second case (Fig. 7B; second case) and the corresponding
release rates as shown in Fig. 6a.
Although PET images do not actually show the entire distribu-
tion of the drug, valuable information can be obtained about the
high and low accumulation zones of the drug in viscous media.
However, the protocol of the PET experiments is not far from what
is applied in vivo during scintigraphy studies, since a watery solu-
tion is injected in human colon without knowing the actual viscos-
ity of the colonic fluids which is presumably higher than that of the
radioactive solution.
3.4. Comparison of the DCM with the compendial mini volume USP 2
dissolution apparatus
Table 1 presents the release rates of theophylline in different
viscous media as published by Stamatopoulos et al. [36]. The
release rates obtained from DCM showed higher variability
between the sampling points compared to the mini volume USP
2; this is a result of the more realistic geometry and motility within
the DCM. However, this means that the comparison of the two dis-
solution apparatuses is not straightforward due to different config-
uration. In DCM tube the medium fills 50% of the tube whereas the
flow is induced by the wall motion as well as by the reflux of the
fluid. In addition, in DCM there is a discontinuous wall motion in
comparison with the continuous impeller rotation in USP 2. Fur-
thermore, in USP 2 the tablet is normally placed within the stag-
nant zone below the shaft in which low velocities [36] and low
shear rates [42] have been reported and which are not changing
as the agitation speed is increased [42]. In contrast the dosage form
faces a dynamic environment in the DCM tube in which disintegra-
16 K. Stamatopoulos et al. / European Journal of Pharmaceutics and Biopharmaceutics 108 (2016) 9–17tion takes place due to the oscillation of the flexible wall. More-
over, by reproducing the architecture of the smooth muscle and
the dimensions of the proximal colon, DCM provides information
about the distribution of the drug with respect to the available sur-
face area of the colonic wall. Moreover, mimicking the variability
in the distribution of the drug could be useful to evaluate the vari-
ability in humans. This is not possible with the compendial disso-
lution methods (e.g. USP 1–4 dissolution apparatus) or with their
improvements like stress test apparatus [5] or with the most
advanced multi-compartmental computer controlled large intes-
tine simulator (TIM-2, TNO) since the volume, dimensions and
the geometry are not relevant to the physical organ [43].
4. Conclusions
A novel in vitro model of the human proximal colon was devel-
oped focusing mainly on the ascending colon. The proposed model
can successfully reproduce the physical amplitudes within the
human colon generated by the wall motion of the Dynamic Colon
Model (DCM) and recorded using a solid state catheter. A direct
association of the magnitude of the pressure signal with the occlu-
sion rate of the membrane and the viscosity of the fluid was found.
Thus a dosage form will experience biorelevant pressures during
its passage through the DCM.
Dissolution experiments of theophylline released from
NaCMC(90,000) based tablets were performed in different viscous
media and under fixed wall motion profile similar to the main
colon motility pattern recorded in vivo in healthy humans [22].
Thus, the disintegration of the tablet and the release of the drug
took place under biorelevant conditions. However, the exact his-
tory of the pressures applied on the tablet during the repeated
wave pressures needs to be investigated by tracking the position
of the tablet. This will allow to evaluate whether the tablet was
phasing pressures within the range measured in the centre of the
contracting point or lower which probably takes place between
the pockets.
The distribution of the drug was determined by collecting sam-
ples from different locations along the DCM tube and performing
Positron Emission Tomography (PET). The results showed areas
of high and low accumulation of the drug. Thus, using the proposed
in vitro model it is possible to assess the behaviour not only of the
dosage form but also how the drug will be distributed along the
human colon, assuming that the more the surface area that the
drug would be exposed the higher the possibility of being absorbed
by the GI tract or the more available for local therapy. In addition,
this information might allow understanding how of phenomena
such as supersaturation and precipitation of the drug during the
passage of the dosage form through the proximal colon.
Further work was required to examine other types of dosage
forms, media volume as well as different motility patterns.
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